NDAORALTABLET
Approved
Nov 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
6/8 — Strong
CARDURA (doxazosin) by Viatris (2) is (bph) the symptoms associated with benign prostatic hyperplasia (bph), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). Approved for hypertension, benign prostatic hyperplasia. First approved in 1990.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDURA (doxazosin) is an oral alpha-1 adrenergic receptor antagonist approved for benign prostatic hyperplasia and hypertension. It works by blocking alpha-1 receptors in the prostate and bladder neck, reducing urethral resistance and improving urine flow, while also decreasing systemic vascular resistance for blood pressure control. The drug addresses both anatomical and functional components of BPH through selective receptor blockade.
$0.338MPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity with minimal Medicare claims activity, the CARDURA brand team faces significant headcount and budget constraints with focus shifting to generic support and managed care negotiations.
Mechanism of Action
(BPH) The symptoms associated with benign prostatic hyperplasia (BPH), such as urinary frequency, nocturia, weak stream, hesitancy, and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to an increase in prostate size…
Indications (2)
Worked on CARDURA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.